Synchron is a clinical-stage endovascular brain-computer interface (BCI) company dedicated to improving the lives of individuals with upper limb impairments. Launched in 2012, Synchron has developed the Synchron Switch™, a minimally invasive BCI that was awarded FDA Breakthrough Device Designation in 2020. Utilizing a novel implantation technique through the jugular vein, the device wirelessly transmits motor intent from the brain, enabling severely paralyzed patients to control personal devices hands-free. With ongoing human clinical trials in the U.S. and Australia, Synchron aims to bring this first-in-class technology to market, addressing the needs of an estimated 100 million people worldwide. The company is characterized by a collaborative, multi-disciplinary team culture that prioritizes innovative problem-solving and supports its mission to restore independence to those facing previously untreatable conditions.